Mymetics Corp (MYMX)

[bow-tie]

Affiliations
1Department of Obstetrics and Gynecology, Division of Vaccine Research, The Ohio State Wexner Medical Center, Columbus, OH, USA.
2Department of Obstetrics and Gynecology, Division of Vaccine Research, The Ohio State Wexner Medical Center, Columbus, OH, USA. [e-mail].
3Arthur G. James Cancer Hospital & Solove Research, Comprehensive Cancer Center, Columbus, OH, USA. [e-mail].
PMID: 33772155 DOI: 10.1038/s41416-021-01342-9
Abstract
We developed a PD-1 B-cell epitope vaccine (PD1-Vaxx) to rival nivolumab therapy which has received ethics approvals for a Phase 1 clinical trial in Australia. The US FDA granted Investigational New Drug approval to Imugene Ltd for clinical testing in NSCLC. We demonstrated synergistic vaccine combinations with an HER-2 targeted vaccine (B-Vaxx).

https://pubmed.ncbi.nlm.nih.gov/33772155/
https://clinicaltrials.gov/ct2/show/NCT04432207